menu
    • menu
    [{"orgOrder":0,"company":"Orbsen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Allogeneic Umbilical Cord Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Orbsen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orbsen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Orbsen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Orbsen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"IRELAND","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Mesenchymal Stromal Cell","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Orbsen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orbsen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Orbsen Therapeutics \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Orbsen Therapeutics

    Menu

    Orbsen Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Orbsen Therapeutics

                            Ireland arrow
                            Tides Europe
                            Not Confirmed

                            Orbsen Therapeutics

                            Ireland arrow
                            Tides Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mesenchymal Stromal Cell

                            Therapeutic Area : Nephrology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Orbsen Therapeutics Announces Encouraging Interim Results from The NEPHSTROM Proof of Concept Clinical Study E...

                            Details : ORBCEL-M is a proprietary formulation of highly purified immunomodulatory stromal cells. It is being developed for adult subjects with type 2 diabetes and progressive diabetic kidney disease (DKD).

                            Product Name : ORBCEL-M

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            January 26, 2023

                            Lead Product(s) : Mesenchymal Stromal Cell

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Orbsen Therapeutics

                            Ireland arrow
                            Tides Europe
                            Not Confirmed

                            Orbsen Therapeutics

                            Ireland arrow
                            Tides Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allogeneic Umbilical Cord Mesenchymal Stem Cell

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Multiverse Investment Fund Announces Portfolio Company’s Commencement of Clinical Trials to Treat ARDS Cause...

                            Details : Orbsen Therapeutics’ proprietary ORBCEL cellular therapy demonstrated the ability to mitigate the effects of ARDS by improving lung oxygenation.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            April 15, 2020

                            Lead Product(s) : Allogeneic Umbilical Cord Mesenchymal Stem Cell

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth